3Q09 financial results and CC transcript;
liquidity and cash usage;
the Lovenox plot may have thickened (Teva CC);
Copaxone continues to clean Tysabri’s clock in US market;
patent application re reverse engineering Copaxone;
3Q09 sales of branded Lovenox;
M118 paper from Nov09 issue of Thrombosis and Hemostasis;
revised table of major shareholders;
revised table of recent biotech buyouts;
index to posts on anticoagulants.

http://investorshub.advfn.com/boards/rea...